Setting the Stage for a Successful TPP: Why (CMC) Should Be a Priority at the Pre-IND Stage
In the race to initiate first-in-human studies, many early-stage biotech companies focus intensively on preclinical data, clinical protocols, and trial design. While these components are essential, one area that is often underestimated—or delayed—is Chemistry, Manufacturing, and Controls (CMC). Yet, overlooking CMC planning at the pre-IND stage can lead to regulatory setbacks, timeline disruptions, and even prevent clinical trials from starting.
For cell and gene therapies (CGT), biologics, and other advanced therapy medicinal products (ATMPs), CMC is not just a technical exercise—it’s a strategic pillar of your development program. Unlike traditional small molecules, the manufacturing process for CGT is intrinsically tied to product identity, safety, and efficacy. Regulators such as the FDA and EMA scrutinize early CMC plans as a proxy for product quality and development readiness.
Key CMC Elements to Address Before Pre-IND
Before entering a Pre-IND meeting, it’s essential to lay a strong foundation for your CMC strategy—particularly when developing complex products like cell and gene therapies. One of the most critical elements is defining and justifying your Critical Quality Attributes (CQAs) early. Attributes such as identity, purity, and potency are central to how regulators evaluate product quality, consistency, and clinical relevance. Without a clear control strategy tied to your product’s intended use, progress through the IND process can stall. Equally important is the traceability and qualification of raw materials. Regulators increasingly expect proof that all components meet GMP standards and are suitable for human application. This is particularly relevant for CGT products, which require the control of materials for complex components such as working cell banks. Furthermore, ensuring that the product under development continues to meet sterility requirements can be challenging if the manufacturing is not conducted using closed systems. Additionally, during early-stage development, the manufacturing is on small scale; progressing to the commercial stage will require scalable systems and streamline processes.
Documenting these strategies early can help preempt regulatory concerns.
Another key area is stability and shelf-life planning, which should align with your intended dosing protocol and storage conditions. Even if limited data are available, real-time and accelerated stability studies reinforce your product’s clinical readiness. This also ties closely to the Target Product Profile (TPP), where usability, shelf-life, and dosage form are critical components.
One of the most common pitfalls in Pre-IND packages is underdeveloped analytical methods—especially for potency assays, which are essential to demonstrate mechanism of action, dose optimization, and expected benefit. These assays should be in place early, and sponsors are encouraged to engage with the FDA to ensure alignment on what is being measured, how, and why.
Having a clear understanding of the body of data that needs to be provided to meet the Module 3/Quality requirements, along with the supporting guidelines, is pivotal for identifying gap and challenging in your product development. It also helps in articulating and formulating specific questions to be address during scientific advice, such as a pre-IND meeting. A well-structured and clearly documented briefing book enhances the productivity of Pre-IND meetings, enabling more collaborative dialogue and the early resolution of potential future regulatory gaps.
For a deeper dive into how to align your potency strategy with FDA expectations, explore our latest whitepaper:
Navigating FDA’s Guidance on Potency Assurance for Cell and Gene Therapy Products
How CMC Planning Shapes the Target Product Profile (TPP)
Your Target Product Profile (TPP) outlines critical elements such as intended use, dosage form, route of administration, and route of administration and shelf-life. Every CMC decision—from formulation to stability testing—should support these attributes.
This is where the Quality Target Product Profile (QTPP) becomes essential. QTPP links your product goals with CMC execution, helping you define specifications, testing, and control strategies that align with long-term commercial success.
A thoughtful CMC strategy isn’t just a regulatory checkbox—it’s a strategic advantage. By planning early, aligning with regulatory authorities expectations such as FDA, and connecting CMC decisions to your TPP, you can move into first-in-human studies with confidence and clarity.
Need help preparing a CMC package that supports both pre-IND alignment and a robust Target Product Profile?
Ergomed’s expert team offers end-to-end CMC regulatory support for cell, gene, and rare disease therapies—from strategy to submission.